• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Lentigen Corporation - Product Pipeline Review - Q4 2010 - Product Image

Lentigen Corporation - Product Pipeline Review - Q4 2010

  • Published: November 2010
  • Region: Global
  • 40 pages
  • Global Markets Direct

Lentigen Corporation – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Lentigen Corporation - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Lentigen Corporation - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Lentigen Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment READ MORE >



List of Tables
List of Figures
Lentigen Corporation Snapshot
Lentigen Corporation Overview
Key Information
Key Facts
Lentigen Corporation – Research and Development Overview
Key Therapeutic Areas
Lentigen Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Lentigen Corporation – Pipeline Products Glance
Lentigen Corporation–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Lentigen Corporation – Drug Profiles
LG611
Product Description
Mechanism of Action
R&D Progress
LG631
Product Description
Mechanism of Action
R&D Progress
LG690
Product Description
Mechanism of Action
R&D Progress
LG747
Product Description
Mechanism of Action
R&D Progress
LG768
Product Description
Mechanism of Action
R&D Progress
LG811
Product Description
Mechanism of Action
R&D Progress
LG889
Product Description
Mechanism of Action
R&D Progress
LG912
Product Description
Mechanism of Action
R&D Progress
LG970
Product Description
Mechanism of Action
R&D Progress
Lentigen Corporation – Pipeline Analysis
Lentigen Corporation – Pipeline Products by Therapeutic Class
Lentigen Corporation Pipeline Products By Target
Lentigen Corporation – Pipeline Products by Route of Administration
Lentigen Corporation – Pipeline Products by Molecule Type
Lentigen Corporation – Locations And Subsidiaries
Head Office
Recent Developments
Dec 09, 2009: Lentigen Awarded Phase I SBIR Grant For Hapatitis C Vaccine
May 30, 2006: Lentigen Corporation And The United States Army Enter Into A Cooperative Research And Development Agreement (LG811)
May 30, 2006: Lentigen Corporation And The United States Army Enter Into A Cooperative Research And Development Agreement (LG611)
May 19, 2006: Lentigen Corporation And The University Of Pennsylvania Enter Intellectual Property License Agreement For Lentiviral Vector Technology (LG611)
May 19, 2006: Lentigen Corporation And The University Of Pennsylvania Enter Intellectual Property License Agreement For Lentiviral Vector Technology (LG811)
Dec 13, 2005: Lentigen Corporation's (LG611) Receives Funding From The State Of Maryland
Dec 13, 2005: Lentigen Corporation Receives Funding From The State Of Maryland (LG811)
Financial Deals Landscape
Lentigen Corporation, Deals Volume Summary, 2004 to YTD 2010
Lentigen Corporation, Deals Summary By Region, 2004 to YTD 2010
Lentigen Corporation, Deals Summary, 2004 to YTD 2010
Lentigen Corporation Detailed Deal Summary
Venture Financing
Lentigen Secures Seed Round Of Financing
Lentigen Secures Series A Round Of Financing
Thermo Fisher Scientific Enters Into An Agreement With Lentigen
Licensing Agreements
Lentigen Enters Into Licensing Agreement With Case Western Reserve University
Lentigen Enters Into Licensing Agreement With Evrogen
ZGene Enters Into Licensing Agreement With Lentigen
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS